Recipharm AB publishes its interim report January - June 2019
April – June 2019 · Net sales amounted to SEK 1,867 million (1,701), an increase of 10% · EBITDA increased by 15% and amounted to SEK 354 million (307) corresponding to an EBITDA margin of 19.0% (18.1) · Operating profit (EBIT) amounted to SEK 171 million (262) · Profit after tax amounted to SEK 94 million (165) corresponding to a net margin of 5.0% (9.7) · Earnings per share amounted to SEK 1.38 (2.56) before dilution and SEK 1.38 (2.50) after dilution · Previous years EBIT and profit after tax were positively affected by SEK 97 million from the divestment of Thyrosafe,